Drug Treatments for Neurodevelopmental Disorders: Targeting Signaling Pathways and Homeostasis.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Neurodevelopmental disorders (NDDs) are increasingly recognized as synaptic disorders with an excitatory-inhibitory imbalance.
• Traditional drug development targeting glutamate or GABA receptors has yielded limited success in NDDs.
• Recent therapeutic advances in Rett syndrome (RTT) and fragile X syndrome (FXS) indicate potential in alternative mechanisms.

Purpose of the Study:

• To review the underlying basis for recent successful drug trials in neurodevelopmental disorders.
• To identify commonalities in successful therapeutic strategies for NDDs.

Main Methods:

• Review of preclinical and clinical evidence.
• Analysis of genetic variants associated with NDDs.
• Examination of pathophysiology, including metabolic and cell signaling pathways.

Main Results:

• Genetic variants in NDDs often implicate cell regulation proteins rather than direct neurotransmission.
• Mitochondrial function and distinctive cell signaling abnormalities are implicated in NDD pathophysiology.
• Successful NDD treatments, like trofinetide for RTT, target downstream signaling pathways, not solely neurotransmitter receptors.

Conclusions:

• Targeting cellular and synaptic homeostasis through signaling pathways represents a promising therapeutic strategy for NDDs.
• This approach may offer a more effective way to ameliorate synaptic abnormalities across various NDDs.